Clinical Trials

The James Cancer Center Columbus, OH

open for enrollment

Ph 1 ACTR707, in Comb w/ Rituximab, in Relapsed/Refractory CD20+ B Cell Lymphoma

Protocol: OSU-17170

Full Title

Phase 1 Study of ACTR707, an Autologous T Cell Product, in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20+ B Cell Lymphoma

Lymphoma Non-Hodgkin’s Lymphoma (B- & T-Cell)